Holen Sie sich die Stockscreener-App
3.18
4.22%
-0.14
Handel nachbörslich:
3.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences director Ilan Ganot sells $447 in stock - MSN
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
Solid Biosciences director Ilan Ganot sells $447 in stock By Investing.com - Investing.com Australia
Solid Biosciences stock hits 52-week low at $3.02 - Investing.com
Solid Biosciences stock hits 52-week low at $3.02 By Investing.com - Investing.com UK
Brokers Set Expectations for SLDB FY2025 Earnings - Defense World
Solid Biosciences gets FDA Fast Track for FA gene therapy By Investing.com - Investing.com Australia
Cantor Fitzgerald Comments on SLDB FY2025 Earnings - MarketBeat
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.30 Average PT from Brokerages - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart - Seeking Alpha
Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Garners Fast Track Designation - CGTLive™
Solid Biosciences gets FDA Fast Track for FA gene therapy - Investing.com India
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation - MarketWatch
Solid Biosciences Secures FDA Fast Track Status for Novel Dual-Route Friedreich's Ataxia Gene Therapy - StockTitan
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia - Yahoo Finance
Barclays PLC Acquires 50,582 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Initiates Clinical Trial For Duchenne Therapy SGT-003 - RTTNews
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines - The Manila Times
Solid Bio draws buy from Truist on valuation and catalysts - MSN
Jane Street Group LLC Has $145,000 Stock Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock By Investing.com - Investing.com Australia
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock - Investing.com India
Kevin Tan Sells 4,073 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences' SWOT analysis: gene therapy firm's stock poised for growth - Investing.com
Q1 EPS Forecast for Solid Biosciences Reduced by Analyst - Defense World
HC Wainwright Reiterates “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World
Solid Biosciences stock hits 52-week low at $3.78 By Investing.com - Investing.com Australia
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from HC Wainwright - MarketBeat
Solid Biosciences stock hits 52-week low at $3.78 - Investing.com
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga
Solid Bio stock draws buy from Truist (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
FDA Nod Sends Solid Biosciences (SLDB) Soaring After-Hours - Stocks Telegraph
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia - Yahoo Finance
FDA clears Solid Biosciences' gene therapy IND for FA By Investing.com - Investing.com South Africa
Solid Biosciences director Ilan Ganot sells $4,551 in stock By Investing.com - Investing.com Canada
FDA clears Solid Biosciences' gene therapy IND for FA - Investing.com India
Solid Biosciences director Ilan Ganot sells $4,551 in stock - Investing.com
Solid Biosciences Gains FDA Clearance for New Drug Application - MarketWatch
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):